Results from the TransATAC trial show that Myriad Genetics Inc.'s EndoPredict and NanoString Technologies Inc.'s Prosigna second-generation tests are superior to Genomic Health Inc.'s Oncotype Dx first-generation test for predicting the long-term recurrence of breast cancer.
TransATAC “answers a critically important unmet need/question, which is how to we best manage patients with breast cancer after they've...